The FDA granted Orphan Drug Designation for KER-065, a therapeutic being developed by KROS for DMD.
1 report, 1 independent
Updated Aug 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Orphan Drug Designation for KER-065, a therapeutic being developed by KROS for DMD.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- The FDA identified deficiencies in a drug application submitted by Aquestive Therapeutics, Inc.
- FDA provided guidance for HCW Biologics' IND application.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- Immix Biopharma's drug NXC-201 is seeking BLA approval from the FDA and received Orphan Drug Designation from the EMA.
Coverage
Newest first; wire copies grouped- GlobeNewswireKeros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Ker